Physician profile
Gary E Schwartz
NPI 1558438481
$857.81
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $135 · 2021: $19.02 · 2022: $58.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $373.52 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.42 | 2019-2020 | |
| Celgene Corporation | $89.15 | 2019 | |
| Amgen INC. | $80.73 | 2019-2020 | |
| Genzyme Corporation | $57.31 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $42.16 | 2019-2021 | |
| Secura Bio, INC. | $30.82 | 2019-2020 | |
| Incyte Corporation | $26.04 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $23.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.